Skip to main content
Clinical Trials/NCT06970054
NCT06970054Not yet recruitingNot Applicable

Home Oscillatory Positive Expiratory Pressure Combined With Aerobic Exercise in Moderate to Severe COPD Patients: A Multicenter, Randomized Controlled Study

Sir Run Run Shaw Hospital1 site in 1 country312 target enrollmentStarted: May 1, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
312
Locations
1
Primary Endpoint
Hospitalization Rates of AECOPD

Study Overview

Brief Summary

The goal of this clinical trial is to evaluate the feasibility and effectiveness of home OPEP therapy and aerobic exercise training in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who are at high risk of acute exacerbations, aged 40-80 years. The main questions it aims to answer are:

Does home OPEP therapy, aerobic exercise training, or the combination of both reduce the incidence and hospitalization rate of acute exacerbations of COPD compared to conventional treatment? What are the effects of these interventions on 6-minute walk distance, all-cause mortality, lung function, quality of life, and treatment adherence? Researchers will compare a) conventional treatment, b) OPEP therapy, c) aerobic exercise training, and d) OPEP therapy combined with aerobic exercise training to see if OPEP therapy and/or aerobic exercise training improve pulmonary rehabilitation outcomes.

Participants will:

Receive assigned intervention based on the study arm (conventional treatment, OPEP therapy, aerobic exercise, or combined therapy).

Use respiratory training devices and/or wearable monitoring devices as required by their assigned group.

Follow training plans and therapy schedules. Attend follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months.

Complete questionnaires and undergo assessments (e.g., lung function tests, 6-minute walk tests) at baseline and follow-up visits.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
40 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age 40-80 years.
  • •Diagnosis of AECOPD according to 2025 GOLD criteria, GOLD stage 2-
  • •Patients seeking treatment for acute exacerbation of COPD (AECOPD) as outpatients or inpatients.
  • •Residing in the study center area with no plans to relocate during the study.
  • •Voluntary participation with signed informed consent.

Exclusion Criteria

  • •Inability to walk or tolerate the 6-minute walk test.
  • •Inability to cooperate with lung function tests.
  • •Life expectancy <6 months (e.g., uncontrolled advanced malignancy, recent MI, unstable angina, acute stroke, acute heart failure).
  • •Active pulmonary tuberculosis or history of lung resection.
  • •Pregnancy or lactation.
  • •Liver or kidney failure requiring dialysis.
  • •Participation in other drug clinical trials or interventional studies.
  • •Vulnerable populations (e.g., mental illness, cognitive impairment, critically ill, illiterate).
  • •Other reasons deemed unsuitable by the researcher.

Arms & Interventions

OPEP only

Experimental
  • Patients are provided with an internet-connected handheld respiratory training device.
  • Patients are provided with a wearable device for monitoring data.
  • Patients receive an OPEP training plan and instructions on using the respiratory training device.
  • Training on the OPEP device is conducted:
  • Inpatients: Twice daily training during hospitalization.
  • Outpatients: At least 3 training sessions in the clinic after enrollment.
  • Treatment compliance is monitored remotely via the IoT system for 8 weeks.
  • Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).

Intervention: OPEP (Device)

Aerobic Exercise Group

Experimental
  • Patients are provided with a wearable device for monitoring data.
  • Patients receive an aerobic exercise training plan and instructions on using the device.
  • Exercise training is conducted:
  • Inpatients: Daily aerobic exercise during hospitalization.
  • Outpatients: At least 3 training sessions in the clinic after enrollment.
  • Treatment compliance is monitored remotely via the IoT system for 8 weeks.
  • Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).

Intervention: Aerobic Exercise (Behavioral)

OPEP and Aerobic Exercise

Experimental
  • Patients receive both an internet-connected handheld respiratory training device and a wearable device.
  • Patients receive OPEP and aerobic exercise training plans and instructions.
  • Training is conducted:
  • Inpatients: Twice daily OPEP training and daily aerobic exercise during hospitalization.
  • Outpatients: At least 3 training sessions in the clinic after enrollment.
  • Treatment compliance is monitored remotely via the IoT system for 8 weeks.
  • Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).

Intervention: OPEP (Device)

OPEP and Aerobic Exercise

Experimental
  • Patients receive both an internet-connected handheld respiratory training device and a wearable device.
  • Patients receive OPEP and aerobic exercise training plans and instructions.
  • Training is conducted:
  • Inpatients: Twice daily OPEP training and daily aerobic exercise during hospitalization.
  • Outpatients: At least 3 training sessions in the clinic after enrollment.
  • Treatment compliance is monitored remotely via the IoT system for 8 weeks.
  • Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).

Intervention: Aerobic Exercise (Behavioral)

Control

No Intervention
  • Patients are advised to maintain their usual activity levels.
  • Patients continue with their prescribed medications.
  • Patients receive routine management, including outpatient education.
  • No specific interventions like respiratory training devices or structured exercise programs are provided.
  • Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).

Outcomes

Primary Outcomes

Hospitalization Rates of AECOPD

Time Frame: Over the 24-month follow-up period

Hospitalization rate of moderate to severe acute exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD). Acute exacerbation of COPD is defined according to the Chinese expert consensus on diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (revised edition 2023)

Incidence of AECOPD

Time Frame: Over the 24-month follow-up period

Incidence of moderate to severe acute exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD). Acute exacerbation of COPD is defined according to the Chinese expert consensus on diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (revised edition 2023)

Secondary Outcomes

  • 6-Minute Walk Distance(1, 2, 6, 12, 24 months, and over 24 months)
  • All-Cause Mortality(24 months)
  • St. George's Respiratory Questionnaire (SGRQ) Score(1, 2, 6, 12, and 24 months)
  • Changes in Lung Function Parameters - MMEF(1, 2, 6, 12, and 24 months)
  • Changes in Blood Gas Parameters - pH(1, 2, 6, 12, and 24 months)
  • Number of Acute Exacerbations(1, 2, 6, 12, 24 months, and over 24 months)
  • Proportion of Participants with ≥2 Acute Exacerbations(24 months)
  • Time to First Acute Exacerbation(24 months)
  • COPD Assessment Test (CAT) Score(1, 2, 6, 12, and 24 months)
  • Modified Medical Research Council (mMRC) Dyspnea Score(1, 2, 6, 12, and 24 months)
  • Changes in Lung Function Parameter-FVC(1, 2, 6, 12, and 24 months)
  • Changes in Lung Function Parameter-FEV1(1, 2, 6, 12, and 24 months)
  • Changes in Lung Function Parameters - FEV1 predicted(1, 2, 6, 12, and 24 months)
  • Changes in Lung Function Parameters - FEV1/FVC ratio(1, 2, 6, 12, and 24 months)
  • Changes in Lung Function Parameters - PEF(1, 2, 6, 12, and 24 months)
  • Changes in Blood Gas Parameters - PaO2(1, 2, 6, 12, and 24 months)
  • Changes in Blood Gas Parameters - PaCO2(1, 2, 6, 12, and 24 months)
  • Changes in Blood Gas Parameters - PaO2/FiO2(1, 2, 6, 12, and 24 months)
  • Changes in Blood Gas Parameters - HCO3(1, 2, 6, 12, and 24 months)
  • Treatment Compliance(1, 2, 6, 12, and 24 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Huiqing Ge

Director of Respiratory Care Department

Sir Run Run Shaw Hospital

Study Sites (1)

Loading locations...

Similar Trials